Team:Brasil-SP/TheIssue
From 2014.igem.org
(Difference between revisions)
Line 108: | Line 108: | ||
<br> | <br> | ||
<br> | <br> | ||
- | <td style="border:1px color= | + | <td style="border:1px color=#D9D9D9;" colspan="1" align="left" height="3px" bgColor=#D9D9D9> |
<img src="https://static.igem.org/mediawiki/2014/f/f7/IconOURSOLUTIONBRASILSP.png"> | <img src="https://static.igem.org/mediawiki/2014/f/f7/IconOURSOLUTIONBRASILSP.png"> | ||
- | <td style="border:0px color= | + | <td style="border:0px color=#D9D9D9;" colspan="3" align="right" height="9px" bgColor=#D9D9D9> |
- | <p><div align="justify" style="color:#000000"><br> | + | <p><div align="justify" style="color:#000000"><br><p><div align="justify"> Several studies support Cystatin C as the best biomarker of renal dysfunction when compared to classical biomarkers (urea nitrogen and serum creatinine), because Cystatin C is very sensitive to changes in GFR (SHLIPAK and DAY, 2013). However, the available methods to evaluate the levels of Cystatin C are often very expensive and inefficient, such as the immunofluorescence method (SHLIPAK and DAY, 2013). Our solution to this problem is to develop a genetic circuit to detect different levels of Cystatin C in the blood. When the detectable levels of Cystatin C are higher than the normal, it will lead us to diagnose CKD and other renal dysfunctions in early stages. The genetic circuit is shown in the Figure below and the input information is based on Cystatin C inhibitory activity against cysteine proteases, in this case, cathepsin S.</div></p> |
+ | <br> | ||
+ | <br> | ||
+ | <img src="https://static.igem.org/mediawiki/2014/f/fb/Detection_module.png" width="500" height="270" align="center"> | ||
+ | <br> | ||
+ | <br> | ||
<h6><p><div align="right"> <b>References</b></div></p> | <h6><p><div align="right"> <b>References</b></div></p> | ||
- | + | <p><div align="right"> SHLIPAK MG, DAY, EC. Biomarkers for incident CKD: a new framework for interpreting the literature. <b>Nature Review on Nephrology</b>, 2013, 9(8):478-83. doi: 10.1038/nrneph.2013.108.</div></p></h6> | |
- | <p><div align="right">SHLIPAK MG, DAY, EC. Biomarkers for incident CKD: a new framework for interpreting the literature. <b>Nature Review on Nephrology</b>, 2013, 9(8):478-83. | + | |
- | + | ||
- | </div></p></h6> | + | |
- | + | ||
</td> | </td> | ||
</tr> | </tr> |
Revision as of 21:35, 12 October 2014